Skip to main content
. 2015 Mar 1;2015:264317. doi: 10.1155/2015/264317

Table 1.

Clinical data in DHLI syndrome and SKYD syndrome groups *.

Characteristics DHLI group
(n = 45)
SKYD group
(n = 45)
P value
Male 26 (57.8) 21 (45.7) 0.291
Age-year 39.0 ± 8.6 36.6 ± 8.9 0.192
Medication history
 SASP 5 (11.11) 6 (13.33) 1.000
 5-ASA 19 (42.22) 21 (46.67) 0.416
 TCM 11 (24.45) 7 (15.56) 0.430
 Integrative treatment 10 (22.22) 11 (24.45) 1.000
Disease type
 Initial onset type# 13 (28.9) 2 (3.4) 0.002
 Chronic persistent type 15 (33.3) 19 (42.2) 0.384
 Chronic relapsing type 17 (37.8) 24 (53.3) 0.138
Active phase# 31 (68.9) 19 (42.2) 0.011
Remission phase# 14 (31.1) 26 (57.7) 0.011
Disease level
 Mild 12 (26.7) 16 (35.6) 0.362
 Middle 29 (64.5) 28 (62.2) 0.827
 Severe 4 (6.9) 1 (2.2) 0.167
Duration of disease
60 months# 19 (42.2) 10 (22.2) 0.042
 >60 months# 26 (57.8) 35 (77.8) 0.042
Clinical activity index# 7.4 ± 2.3 6.4 ± 2.1 0.036
Endoscopic index# 6.0 ± 2.2 4.8 ± 1.7 0.010
Biopsy type
 0 8 (17.8) 11 (24.4) 0.438
 1 10 (22.2) 8 (17.8) 0.598
 2 12 (26.7) 13 (28.9) 0.814
 3 8 (17.8) 7 (15.6) 0.777
 4 3 (6.7) 4 (8.9) 0.694
 5 4 (8.9) 2 (4.4) 0.398

   *Data was presented as case number (%). Age, clinical activity index, and endoscopic index were displayed as mean ± SD.

# P < 0.05. There was significant difference between the DHLI and SKYD groups.

0, structural change only; 1, chronic inflammation; 2, lamina propria neutrophils; 3, neutrophils in epithelium; 4, crypt destruction; and 5, erosions or ulcers [18].